PennyStocksUpdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 10/25/2012 -- Dice Holdings (NYSE:DHX) announced its earnings results on Wednesday. The company reported $0.17 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.12 by $0.05. Dice Holdings’s revenue was up 2.6% compared to the same quarter last year. Shares of DHX are trading at $9.20 and is +8.83% of its 50-day Moving Average price of $8.4533 and +2.57% from its 200-day Moving Average price of $8.9696. The average trading volume is 649852 shares and its market capitalization is $571.5M.
How Should Investors React To DHX Now? Find Out Here
Monster Beverage Corp. (NASDAQ:MNST) rallied nearly 13% to $46.20 in early trades on Wednesday, as the top gainer in the S&P 500 (US:$spx), after the company defended the safety of its energy drinks. The stock fell 10% on Tuesday. The monster said late Tuesday a 24-ounce can contains less caffeine than a 16-ounce cup of coffee. The company was reacting to a lawsuit and reports that the Food and Drug Administration has received word of five deaths citing its drinks. On Tuesday, Goldman Sachs removed Monster Beverage from its Conviction Buy list, but kept its buy rating on the stock. Goldman Sachs downgraded shares of Monster Beverage Corp (MNST) to a buy rating. Their analysts now have a $62.00 price target on the stock. They also removed the stock from their conviction buy list. They also removed the stock from their conviction buy list.
How Should Investors Trade MNST Now? Free Sign Up Here
Molina Healthcare Inc (NYSE:MOH) surged up 13.55% and the last traded price was $25.81 with a traded volume of 1.57 million shares after the Company released third quarter results. Net income was $3.4 million or $0.07 per diluted share compared to net income of $19.0 million or $0.41 per diluted share in the prior year period. Earnings per diluted share for third quarter 2012 were $0.07 compared to $0.41 in the third quarter of 2011.Quarterly premium revenues increased 31% to $1.5 billion. Aggregate membership soared 9%.
Get Free Trend Analysis on To Know More About MOH Here
Analysts at Leerink downgraded NuVasive (NASDAQ:NUVA) from “outperform” to “market perform.” NuVasive's shares closed at $14.27 yesterday. NuVasive's trailing-twelve-month profit margin is -12.57%. NuVasive Inc (NASDAQ:NUVA) escalated 12.81% and closed at $14.27 on a traded volume of 4.11 million shares. The Company expects to report third quarter revenues of approximately $147 million. The consensus estimate is for revenue of $153.62 million.
How Should Investors Trade NUVA Now? Find Out Here
DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..
Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)